# The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis

> **NCT03455842** · PHASE2 · COMPLETED · sponsor: **Biocad** · enrollment: 105 (actual)

## Conditions studied

- Seropositive RA

## Interventions

- **BIOLOGICAL:** BCD-089, 162 mg, s/c, qw
- **BIOLOGICAL:** BCD-089, 162 mg, s/c, q2w
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03455842
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-10-22
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2021-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455842, "The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03455842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*